TNFRSF8 and Hodgkins lymphoma: Among them, LT4 and CAM29 inhibited the release of CD30, which enhanced the biological effect of the anti-tumor agent Brentuximab Vedotin on Hodgkin lymphoma cells, and interfered with exosome exchange between Hodgkin lymphoma cells and lymph node stromal cells, thereby affecting the activity of α-secretase (Tosetti et al., 2018).